KKR, a global investment firm that offers alternative asset management as well as capital markets and insurance solutions, and OMX Ventures, an early stage, tech-bio focused venture capital fund, led a $55m Series A funding round in Replay, a genome writing company reprogramming biology by writing and delivering big DNA, with participation from ARTIS Ventures, Lansdowne Partners, SALT, DeciBio Ventures, and Axial. “Genomic medicine has the potential to transform the future of clinical therapeutics. Over my three decades of experience working in clinical medicine, academia, and the biopharmaceutical industry, it has become clear that we require a more robust and comprehensive toolkit of molecular genetic platform technologies to solve biology’s most complex problems and realize its full therapeutic potential. In Replay we have assembled a world-class team of entrepreneurs, subject matter experts, and cutting-edge genomic medicine and synthetic biology technologies into a coherent structure that will enable us to address medicine’s greatest challenges, including solid tumors and polygenic diseases," Adrian Woolfson, Executive Chairman, Replay President, and Co-founder.